1Opelz G, Dt+hler B. Influence of immunosuppressive regimens on graft survival and secondary outcomes after kidney transplantation [ J ]. Transplantation, 2009, 87 (6) : 795-802.
2Jiang WJ, Lu YP. KDIGO clinical practice guideline: diagnosis and treatment on renal transplant recipients [J/CD]. Chin J Transplant: Electronic Edition, 2010, 4 (2): 156-164.
3Mariat C, Afiani A, Alamartine E, et al. A pilot study comparing basiliximab and anti-thymocyte globulin as induction therapy in sensitized renal allograft recipients [J]. Transplant Proc, 2001, 33 (7/8): 3192-3193.
4Ji SM, Li LS, Cheng Z, et al. A single-dose daclizumab induction protocol in renal allograft recipients: a Chinese single center experience [ J ] . Transplant Proc, 2007, 39 (5): 1396-1401.
5Gonzrlez E, Gutirrrez E, Hemrndez Y, et al. Anti-CD25 monoclonal antibody sequential immunosuppressive induction therapy in renal transplants with high risk of delayed graft function [ J ]. Transplant Proc, 2005, 37 (9): 3736-3737.
6Hammond EB, Taber DJ, Weimert NA, et al. Efficacy of induction therapy on acute rejection and graft outcomes in African American kidney transplantation [ J ]. Clin Transplant, 2010, 24 (1): 40-47.
7Gaudio MD, Ravaioli M, Ercolani G, et al. Induction therapy with alemtuzumab (eampath) in combined liver- kidney transplantation: university of bologna experience [J]. Transplant Proe, 2013, 45 (5): 1969-1970.
